Latest News and Events
Filter by
Selections
February 22, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreFebruary 15, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
Read MoreJanuary 22, 2018
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
Read MoreJanuary 18, 2018
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
Read MoreJanuary 17, 2018